Skip to main content

Identification of new angiogenic regulatory events, markers and targets for anti- or pro-angiogenic therapies (ANGIONET)

Objective

A wide range of common and lethal pathologies such as cardiovascular diseases, tumour growth and metastatic spread, are linked to the disruption of the angiogenic balance. The antiangiogenic treatments currently in clinical trials for cancer generally target a limited number of events involved in the angiogenic process. There is a pressing need to expand the number of therapeutic targets in this area. The consortium partner laboratories contribute expertise on a wide spectrum of cellular and in vivo models, providing a comprehensive representation of specific steps in neovascularization. These models will be processed by genomics analysis and promising genes will be pre-selected in vitro. The selected genes will be assessed and compared in the set of physiological and pathological models. This strategy will lead to the identification of novel critical genes and define their role in angiogenesis.

Funding Scheme

CSC - Cost-sharing contracts
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AVENTIS PHARMA RECHERCHE DEVELOPPEMENT S.A.
Address
Quai Jules Guesde 13
94403 Vitry Sur Seine
France

Participants (4)

FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY VZW
Belgium
Address
49,Herestraat 49 Kul / Campus Gasthuisberg
3000 Louvain / Leuven
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Germany
Address
Benekestrasse 2
61231 Bad Nauheim
TUMOR BIOLOGY CENTRE FREIBURG
Germany
Address
Breisacher Strasse 117
79106 Freiburg (In Breisgau)
UNIVERSITY OF HELSINKI
Finland
Address
3,Haartmaninkatu 8
00014 Helsinki